US · RVPH
Reviva Pharmaceuticals Holdings, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Cupertino, CA 95014
- Website
- revivapharma.com
Price · as of 2024-12-31
$0.88
Market cap 14.64M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | $8.48 | ||||
| 2021 | $1.70 | ||||
| 2022 | $4.41 | ||||
| 2023 | $3.50 | ||||
| 2024 | $1.15 |
AI valuation
Our deep-learning model estimates Reviva Pharmaceuticals Holdings, Inc.'s (RVPH) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $0.88
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| RVPH | Reviva Pharmaceuticals Ho… | $0.88 | 14.64M | — | — | — | — | -1.27 | 46.91 | — | -0.84 | — | 46.91 | 0.00% | — | — | -916.17% | 206.33% | -152.63% | 0.56 | -1665.07 | 1.01 | 0.92 | 0.44 | -4545.00% | — | 1843.00% | -88.00% | -2.30 | 224.72% | 0.00% | 0.00% | 0.00% | -0.82 | -0.75 | — | -19.83 |
| ANVS | Annovis Bio, Inc. | $2.68 | 52.73M | — | — | — | — | 0.00 | 2.28 | — | -0.40 | 0.00 | 2.28 | 0.00% | — | — | -3159092.37% | 361.97% | -203782.88% | 0.00 | -14.40 | 3.59 | 2.72 | 0.40 | 3215955.00% | — | 5468129.00% | -103292.61% | -5641.50 | 296879.29% | 0.00% | 0.00% | 22.63% | -0.40 | 0.00 | — | -16.26 |
| BCAB | BioAtla, Inc. | $0.25 | 14.5M | — | +725% | — | — | -0.24 | 1.17 | 1.52 | 0.43 | — | 1.17 | 91.59% | -672.21% | -634.33% | -164.30% | 204.59% | -81.10% | 0.06 | — | 3.52 | 3.37 | 0.66 | -4419.00% | — | -3091.00% | -429.27% | -4.95 | 199.04% | 0.00% | 0.00% | 0.00% | 0.43 | 0.44 | -2.86 | -16.32 |
| BTAI | BioXcel Therapeutics, Inc… | $1.67 | 36.52M | +9,886% | -19% | — | — | -0.14 | -0.09 | 3.77 | -1.85 | — | -0.09 | 5.43% | -2967.56% | -2630.14% | 79.67% | 333.28% | -106.39% | -1.11 | -4.44 | 1.68 | 1.35 | -1.66 | -7610.00% | 6420.00% | -5354.00% | -843.12% | -3.24 | 356.98% | 0.00% | 0.00% | 0.00% | -1.21 | -1.13 | 36.03 | -28.96 |
| CELU | Celularity Inc. | $1.23 | 29.59M | +3,881% | -60% | — | — | -0.47 | 3.05 | 0.50 | -2.17 | — | -3.47 | 72.36% | -70.75% | -106.77% | -232.51% | -41.90% | -41.86% | 7.79 | -6.12 | 0.38 | 0.27 | -1.56 | -7600.00% | 13811.00% | -8464.00% | -24.37% | -0.12 | -7.17% | 0.00% | 0.00% | 0.00% | -2.48 | -14.48 | 1.75 | -10.21 |
| EVAX | Evaxion Biotech A/S | $3.16 | 19.96M | +25,906% | -76% | — | — | -0.19 | -1.22 | 0.60 | -0.72 | — | -1.22 | 100.00% | -440.55% | -316.00% | 331.20% | -693.28% | -83.29% | -6.11 | -15.31 | 2.01 | 1.58 | -0.52 | -6975.00% | 448082.00% | -2721.00% | -641.54% | -2.96 | -654.36% | 0.00% | 0.00% | 11.80% | -0.48 | -0.55 | 2.11 | -16.41 |
| FGEN | FibroGen, Inc. | $9.07 | 36.69M | +230% | -59% | — | +42% | -19.49 | -4.11 | 31.31 | -6.67 | — | -4.11 | 47.47% | -507.80% | -160.63% | 22.14% | 63.58% | -14.91% | -0.32 | -18.24 | 1.47 | 0.60 | -0.16 | -8356.00% | -3671.00% | -5646.00% | -14.91% | -1.04 | 58.55% | 0.24% | -4.70% | 3.92% | -6.32 | -6.87 | 32.07 | -12.76 |
| PDSB | PDS Biotechnology Corpora… | $0.68 | 36.94M | — | — | — | — | -1.19 | 2.36 | — | -0.74 | — | 2.36 | 0.00% | — | — | -166.65% | 954.97% | -71.81% | 1.15 | -7.77 | 2.64 | 2.44 | 0.59 | -2590.00% | — | 423.00% | -78.19% | -2.05 | 943.09% | 0.00% | 0.00% | 0.00% | -0.69 | -0.71 | — | -6.50 |
| PYPD | PolyPid Ltd. | $4.25 | 43.31M | — | — | — | — | -2.08 | 6.47 | — | -1.91 | — | 6.47 | 0.00% | — | — | -366.29% | -2641.59% | -143.79% | 0.25 | -48.13 | 1.97 | 1.67 | 0.11 | -5743.00% | — | -10000.00% | 0.00% | 0.00 | 0.00% | 0.00% | 0.00% | 0.00% | -1.84 | — | — | -19.64 |
| TVRD | Tvardi Therapeutics, Inc. | $3.99 | 37.43M | +2,851% | +48% | — | +64,129% | -0.32 | -4.89 | 3.15 | -0.46 | -0.01 | -4.89 | 88.62% | -781.57% | -992.95% | 212.65% | 134.22% | -200.11% | -9.68 | -6.58 | 11.03 | 10.67 | -0.10 | 241838.00% | -6596.00% | 19450.00% | -276.02% | -15.34 | 149.93% | 0.00% | 0.00% | 0.00% | -0.52 | -0.47 | 4.06 | -26.80 |
About Reviva Pharmaceuticals Holdings, Inc.
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is headquartered in Cupertino, California.
- CEO
- Laxminarayan Bhat
- Employees
- 14
- Beta
- 0.04
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $0.88) − 1 = — (DCF, example).